12:00 AM
 | 
Aug 01, 2005
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/29 cls
Amylin (AMLN) C.E. Unterberg, Towbin Matthew Osborne Downgrade Market perform (from buy) -12% $18.66
Osborne believes that impatient investors may find the ramp in prescriptions for Byetta to treat Type II diabetes to be disappointing over the next few months, although they are on track with his expectations.
Applied Bio (ABI) Pacific Growth Adam Chazan Other Underweight 5% $20.82
SG Cowen Eric Schmidt Other NA
Chazan raised his FY06 EPS estimate to $1.10 from $1.08 and his FY06 revenue estimate to $1.86B from $1.84B after ABI reported fiscal 4Q05 revenue and EPS of $478.5M and $0.31. Chazan was expecting $463.7M in revenue and EPS of $0.28. He also introduced 1Q06 estimates of $404M and $0.17. Chazan said ABI continues to trade at a premium to its peers despite a lack of meaningful growth (see "EPS Watch," A18).
Schmidt raised his FY06...

Read the full 918 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >